Grifols, S.A. acquired 32.9% in Progenika Biopharma, S.A. from Minerales y Productos Derivados, S.A. for 25 million.
March 03, 2016 at 09:30 am IST
Grifols, S.A. (BME:GRF) acquired 32.9% in Progenika Biopharma, S.A. from Minerales y Productos Derivados, S.A. (BDM:MYD) for 25 million in cash and stock on March 3, 2016. 50% of the purchase price has been paid in exchange for 876,777 non-voting class B shares of Grifol and rest in cash. Grifols acquired 0.01 million shares in Progenika. Osborne Clarke acted as legal advisor for Grifols. Cuatrecasas Gonçalves Pereira acted as legal advisor for Minerales y Productos.
Grifols, S.A. (BME:GRF) completed the acquisition of an unknown stake in Progenika Biopharma, S.A. from Minerales y Productos Derivados, S.A. (BDM:MYD) on March 3, 2016.